This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Canada
AdeTherapeutics is a privately-held clinical-stage drug development company developing products that deal with complications related to surgery.
AIM Therapeutics Inc., a biotechnology company, engaged in the discovery and development of peptide-based therapeutic candidates for the treatment of asthma, cardiovascular disease, diabetes, spinal cord injury, COPD, restenosis, and other inflammatory and immune disorders.
Akshaya Bio Inc. (Akshaya) is a privately held development stage biotechnology company which develops innovative therapeutics for infectious diseases and cancer. Akshaya's proprietary Chimigen
Alectos Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small-molecule therapeutics for the treatment of serious diseases in the therapeutic areas of oncology and neurology.
Alethia Biotherapeutics is engaged in the discovery of novel targets and development of targeted therapeutics. The company has prioritized the development of monoclonal antibodies against novel clinically relevant targets identified using its STAR target discovery platform.
AllerPharma is a pharmaceutical engaged in the in-licensing, development and commercialization of prescription products that target therapeutic areas in allergy, ophthalmology, dermatology, respirology as well as other specialties.
Alpha Cancer Technologies Inc. (ACT) is a Canadian biotechnology company developing disruptive oncology products based on a unique targeting platform - alpha-fetoprotein conjugated cytotoxins. These products have the potential to dramatically improve cancer therapy for majority of patients by providing superior efficacy and greatly improved safety.
Amorfix Life Sciences Ltd. is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease. The company has developed a core expertise in the field of protein misfolding with its ability to identify regions on proteins that are unique in a diseased state and not in a normal healthy state.
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new EPiC compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others.
Antibe Therapeutics is a human drug development company with a portfolio of patented anti-inflammatory drug candidates targeting significant global markets. The company create improved versions of existing anti-inflammatory drugs by linking an off-patent, 'base' drug to an Antibe-patented compound that releases hydrogen sulfide, resulting in a new drug with significantly improved properties compared with the base drug.
Aquinox is a clinical-stage pharmaceutical company discovering and developing novel oral drug candidates to treat inflammation and cancer. The Company's primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Its lead product candidate, AQX-1125, has demonstrated broad anti-inflammatory activity in vitro and in vivo, and has successfully completed three clinical trials with over 100 patients enrolled to date. Aquinox is currently investigating AQX-1125 in two Phase 2 clinical trials, one for Chronic Obstructive Pulmonary Disease, or COPD, and one for Bladder Pain Syndrome/Interstitial Cystitis, or BPS/IC. COPD and BPS/IC are debilitating chronic inflammatory diseases affecting millions of people worldwide.
ArcticDx is a molecular diagnostic company with a focus on commercializing genetic discoveries. The companies IP portfolio consists of genetic biomarkers for colorectal cancer and age-related macular degeneration.